[1] De Caterina AR, Cuculi F, Banning AP. Incidence, predictors and management of left main coronary artery stent restenosis: a comprehensive review in the era of drug-eluting stents[J].Euro Intervention, 2013, 8(11): 1326-1334.[2] Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies[J]. J Am Coll Cardiol, 2002,39(2):183-193.[3] Colombo A, Ruparelia N. Is a drug-eluting stent the default treatment strategy for drug-eluting stent restenosis? [J]. J Am Coll Cardiol, 2015, 66(1): 34-36.[4] Alfonso F, Sandoval J, Perez-Vizcayno MJ, et al. Mechanisms of balloon angioplasty and repeat stenting in patients with drug-eluting in-stent restenosis[J]. Int J Cardiol, 2015, 178:213-220.[5] Juszkat R, Stanislawska K, Wasik N, et al. Very late in-stent thrombosis 9 years after double stent treatment of fusiform basilar artery aneurysm[J]. Interv Neuroradiol,2015, 21(3): 329-331.[6] Nijhoff F, Stella PR, Troost MS, et al. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis[J]. Clin Res Cardiol,2016,105(5): 401-411.[7] Kang SJ, Lee JY, Ahn JM, et al. Validation of intravascular ultrasound-derived parameters with fractional flow reserve for assessment of coronary stenosis severity[J]. Circ Cardiovasc Interv, 2011, 4(1): 65-71.[8] Ben-Dor I, Torguson R, Deksissa T, et al. Intravascular ultrasound lumen area parameters for assessment of physiological ischemia by fractional flow reserve in intermediate coronary artery stenosis[J]. Cardiovasc Revasc Med, 2012, 13(3): 177-182.[9] Liu J, Wang Z, Wang WM, et al. Feasibility of diagnosing unstable plaque in patients with acute coronary syndrome using iMap-IVUS[J]. J Zhejiang Univ Sci B, 2015, 16(11): 924-930.[10] Klersy C, Ferlini M, Raisaro A, et al. Use of IVUS guided coronary stenting with drug eluting stent: a systematic review and meta-analysis of randomized controlled clinical trials and high quality observational studies[J]. Int J Cardiol, 2013, 170(1): 54-63.[11] Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study[J]. J Am Coll Cardiol, 2010, 55(24): 2710-2716.[12] Ko YG, Kim JS, Kim BK, et al. Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study ) [J]. Am J Cardiol, 2012, 109(5): 607-613.[13] Kufner S, Kastrati A. Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? [J].Coron Artery Dis, 2014, 25(8): 633-635.[14] Xia HY, Low AF, Lee CH, et al. Treatment of coronary in-stent restenosis with drug-eluting balloon catheter: real-world outcome and literature review[J]. Ann Acad Med Singap, 2013, 42(1): 49-51.[15] Minha S, Pichard AD, Waksman R. In-stent restenosis of drug-eluting stents[J]. Future Cardiol, 2013, 9(5): 721-731.[16] Schnorr B, Speck U, Scheller B. Review of clinical data with paccocath-coated balloon catheters[J]. Minerva Cardioangiol, 2011, 59(5): 431-445. |